SameOldDrew wrote:monsterpile wrote:Because Wiggins signed his extension he basically can't be traded this season. I hope Wiggins discussions can stay respectful but why not let this season play out and go from there?
Really? Is that a policy? I didn't know that. How was the Blake deal different? Was he a UFA last summer so it's different?
http://www.cbafaq.com/salarycap.htm#Q91
"91. What is the Poison Pill Provision?
"Poison Pill" isn't a defined term in the CBA, but there are a couple situations that are commonly referred to as a poison pill -- meaning a contract clause that creates a potential difficulty because the cap accounting can vary from the norm.
The first is when a team extends a first round draft pick's rookie scale contract (see question number 58) and then trades the player between the date the extension is signed and the date it takes effect. When this happens, the player's trade value for the receiving team is the average of the salaries in the last year of the rookie scale contract and each year of the extension. The sending team uses the player's actual salary when calculating their total outgoing salary, and uses the current-year maximum salary in place of the (unknown) maximum salary for a future season, if necessary.
For example, if a player on the last year of his rookie scale contract earns $5 million in 2018-19, and his contract is extended for four seasons starting at $10 million, with 5% raises, then his salary in each season will be:
Season Salary
2018-19 $5,000,000
2019-20 $10,000,000
2020-21 $10,500,000
2021-22 $11,000,000
2022-23 $11,500,000
If this player is traded during the 2018-19 season, then his outgoing salary from the sending team's perspective is his actual salary -- $5 million. But the player's incoming salary from the receiving team's perspective is $9.6 million -- the average of all five seasons. Such a player would be very difficult to trade -- a legal trade can only be accomplished if both teams add additional salary to the transaction, or if they include a third team that is able to absorb excess salary.
The Gilbert Arenas provision (see question number 43) also has been described as containing a poison pill. This is in reference to the third season of contracts signed according to this provision, which can contain substantially higher salaries than the first two seasons. Houston used this provision to its advantage when signing Jeremy Lin and Omer Asik in 2012. However, the impact of this poison pill was reduced in the 2017 CBA, when matching teams were given the ability to choose whether the actual or average salary counted toward their team salary."